Tryp Therapeutics – Psychedelic Therapy Beyond Mental Health Care

Jim Gilligan, President and Chief Scientific Officer discusses Tryp Therapeutics, a pharmaceutical company focused on developing psilocybin-based compounds to treat diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s unique Psilocybin-For-Neuropsychiatric Disorders (PFN™) program focuses on developing synthetic psilocybin as a new class of drug for the treatment of chronic pain and other indications. Tryp Therapeutics brings a proprietary and differentiated approach to manufacturing, formulating, dosing, and administering psychedelic compounds, including advancing its novel compound TRP-8803 through preclinical trials with the aim to improve the patient experience and enhance patient safety. 

Jim Gilligan, PhD serves as President and Chief Scientific Officer of Tryp Therapeutics.

Jim was a Co-founder of Unigene Laboratories where he served in a variety of executive leadership positions for nearly 30 years. He subsequently co-founded and served as Chief Scientific Officer of Tarsa Therapeutics and as Co-founder and Managing Partner at The Bracken Group, a life science consulting firm.

Jim earned a BS in biology from Bates College, an MBA from Seton Hall University, and a PhD in pharmacology from the University of Connecticut. He played basketball at Bates College and continued his post-graduate education at the Roche Institute of Molecular Biology.